First human tests of meth medication completed

(Medical Xpress)—InterveXion Therapeutics LLC and the University of Arkansas for Medical Sciences (UAMS) have successfully completed dosing in the first human safety study of a medication to help methamphetamine users fight their addictions.

The medication is expected to significantly reduce or prevent the euphoric rush that crave by keeping methamphetamine in the and out of the brain, where the drug exerts its most powerful effects.

In the Phase I trial, 40 healthy volunteers who do not use methamphetamine received the medication over the past eight months and experienced no serious side effects.

"While we still have lots of work to do, this is a significant milestone for this research," said Brooks Gentry, M.D., a UAMS professor and InterveXion's chief officer who is overseeing the clinical . "Many experimental drugs fail during the first phase of a clinical trial, so we're excited that we can now look forward to testing in methamphetamine users who want help reducing their meth dependence."

When it has received final approval, the antibody will be given as an integral part of a methamphetamine user's complete treatment program, which consists of counseling and possibly other medications to reduce craving.

The medication, named ch-mAb7F9, is a monoclonal antibody. InterveXion, the trial sponsor, contracted the safety study to the Quintiles Phase 1 unit in Overland Park, Kan. The volunteers in the study, who received doses that ranged from 0.2 to 20 mg/kg, will continue to be followed for 21 weeks. Results of the Phase 1a study are expected in mid-2013.

The next steps in the development of the medication include further nonclinical safety testing followed by a Phase 1b clinical safety trial in current methamphetamine users.

Funding for the project was awarded to UAMS and InterveXion from the National Institute on Drug Abuse (NIDA). Additional support was given by the UAMS Translational Research Institute. NIDA has backed the development, manufacture and toxicology testing of this medication through previous grants to InterveXion and UAMS.

InterveXion, a UAMS BioVentures incubator client company, has licensed the technology for anti-methamphetamine antibody products from UAMS and is working closely with the university during product development.

Methamphetamine abuse has been a significant problem in the United States for the last decade. According to the Substance Abuse and Mental Health Services Administration, there were 439,000 methamphetamine users in the U.S. in 2011. New methamphetamine users numbered 133,000. In 2010, more than 100,000 were admitted to drug abuse treatment with methamphetamine as their primary substance of abuse. In addition, there were 54.9 emergency department visits per 100,000 population aged 21 or older involving use.

Related Stories

Toward a vaccine for methamphetamine abuse

May 11, 2011

Scientists are reporting development of three promising formulations that could be used in a vaccine to treat methamphetamine addiction — one of the most serious drug abuse problems in the U.S. The report ...

Recommended for you

Xtoro approved for swimmer's ear

12 hours ago

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

13 hours ago

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.